An October 21 announcement from Elucid introduced the commercial availability of FFR-IQ, software that estimates coronary fractional flow reserve from computed tomography angiography. The key regulatory date is earlier: the FDA's 510(k) substantial-equivalence determination for Elucid FFR-IQ (B.1), submission K262015, is dated September 29, 2026.
The distinction matters because a product announcement and a regulatory decision are separate events. The FDA letter classifies the product as a Class II coronary vascular physiologic simulation software device. Its stated purpose is to support qualified clinicians assessing coronary artery disease using previously acquired CT images. It is not a stand-alone diagnosis, and the labeling specifies that results should be interpreted alongside symptoms, clinical history and other testing.
The software combines coronary anatomical information with AI-enabled estimation of physiological measures. The FDA summary describes a retrospective multicentre validation study that analysed 491 vessels from 347 patients, using invasive fractional flow reserve as a comparator. Such studies can establish performance within a defined population, but their results should not be generalized without considering exclusions, image-quality requirements and how patients were selected.
Elucid's announcement emphasizes the combination of plaque characteristics and coronary physiology. Claims that a product is the most accurate in its class should be attributed to the manufacturer unless a suitable independent head-to-head comparison supports that ranking. The FDA's substantial-equivalence finding should also not be described as a blanket endorsement of every promotional claim.
For health systems, the adoption questions extend beyond clearance: integration with imaging workflows, turnaround time, quality assurance, clinical oversight and performance across diverse populations. This case illustrates why regulatory reporting should preserve the chronology of FDA decisions, commercial launches and subsequent real-world evidence.